Patents by Inventor Meiei Cho
Meiei Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083893Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: May 8, 2023Publication date: March 14, 2024Applicant: National Institutes for Quantum and Radiological Science and TechnologyInventors: Makoto HIGUCHI, Tetsuya SUHARA, Masahiro MARUYAMA, Meiei CHO, Hitoshi SHIMADA
-
Publication number: 20240002313Abstract: [Object] Provided are a 11C-labeled acyclic retinoid that can be synthesized in a short time with a high yield and can be suitably used for PET for elucidating intracerebral kinetics, a PET probe using it, and methods for producing them. [Solution] The 11C-labeled acyclic retinoid of the present invention is characterized by being represented by the following chemical formula (a). This compound can be produced by a coupling step of cross-coupling a methyl iodide labelled with 11C and the following organotin compound (b) (provided that in the formula, R1 and R2 represent alkyl groups which may have a branch) in an aprotic solvent in the presence of a palladium complex, a phosphine ligand, and a cuprous halide.Type: ApplicationFiled: November 18, 2021Publication date: January 4, 2024Applicant: NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGYInventors: Masaaki SUZUKI, Kengo ITO, Yasuyuki KIMURA, Aya OGATA, Hiroshi IKENUMA, Tetsuya KIMURA, Nobuyuki KIMURA, Hiroko KOYAMA, Hideki ISHII, Meiei CHO, Kazunori KAWAMURA, Takafumi MINAMIMOTO, Yuji NAGAI, Hiroshi KATSUKI
-
Publication number: 20230399323Abstract: An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.Type: ApplicationFiled: August 24, 2021Publication date: December 14, 2023Inventors: Makoto Higuchi, Maiko Ono, Meiei Cho, Takeshi Yamamoto, Takeshi Wakabayashi
-
Patent number: 11667628Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: GrantFiled: September 16, 2021Date of Patent: June 6, 2023Assignee: NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGYInventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Publication number: 20220175973Abstract: A method for producing a radiopharmaceutical, the method capable of maintaining a radioactive compound retaining a chemical structure and radioactivity at the time of production and after the production, and maintaining a usable period of a radiopharmaceutical; and a radiopharmaceutical are provided. The method for producing a radiopharmaceutical that has a radioactive component containing a radioactive dithiosemicarbazone copper complex includes: a stabilization step of adding a stabilizing agent containing at least one compound selected from the group consisting of ascorbic acid, methionine, sodium ascorbate, mannitol, and butylhydroxyanisole to a solution containing the radioactive component; and a filtration step of filtering the solution containing the radioactive component or a precursor thereof with a sterilization filter. In the radiopharmaceutical, a concentration of the radioactive component is 200 MBq/mL or more in terms of radioactivity concentrations.Type: ApplicationFiled: February 14, 2020Publication date: June 9, 2022Inventors: Yukie Yoshii, Meiei Cho, Kazunori Kawamura, Hisashi Suzuki, Hiroki Hashimoto
-
Publication number: 20220133698Abstract: The present invention provides an ?-synuclein aggregate binding agent that has high binding selectivity for an ?-synuclein aggregate. The ?-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.Type: ApplicationFiled: January 24, 2020Publication date: May 5, 2022Inventors: Makoto Higuchi, Maiko Ono, Tetsuya Suhara, Meiei Cho
-
Publication number: 20220056020Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: September 16, 2021Publication date: February 24, 2022Inventors: Makoto HIGUCHI, Tetsuya SUHARA, Masahiro MARUYAMA, Meiei CHO, Hitoshi SHIMADA
-
Publication number: 20200262829Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: February 21, 2020Publication date: August 20, 2020Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Patent number: 10604516Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: GrantFiled: December 21, 2012Date of Patent: March 31, 2020Assignee: National Institutes for Quantum and Radiological Science and TechnologyInventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
-
Patent number: 10335503Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.Type: GrantFiled: July 5, 2016Date of Patent: July 2, 2019Assignee: Public University Corporation Yokohama City UniversityInventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
-
Publication number: 20180200391Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.Type: ApplicationFiled: July 5, 2016Publication date: July 19, 2018Applicant: Public University Corporation Yokohama City UniversityInventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
-
Publication number: 20160045625Abstract: A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.Type: ApplicationFiled: April 2, 2014Publication date: February 18, 2016Inventors: Norihito Oi, Noboru Yamamoto, Michiyuki Suzuki, Yosuke Nakatani, Tetsuya Suhara, Meiei Cho, Toshimitsu Fukumura, Makoto Higuchi, Takafumi Minamimoto, Jun Maeda, Masaki Tokunaga, Yuji Nagai
-
Publication number: 20150239878Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.Type: ApplicationFiled: December 21, 2012Publication date: August 27, 2015Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada